Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.
Recordati reported a strong financial performance for 2024 with consolidated net revenues of €2,341.6 million, showing a 12.4% increase. The company’s notable achievements include the acquisition of Enjaymo® from Sanofi and the upward revision of sales targets for its key rare disease products. The growth in the Rare Diseases segment was driven by products like Isturisa® and Qarziba®, contributing to the company’s robust market positioning. The inclusion in the FTSE4GOOD Index and an ESG ‘A’ rating by MSCI highlight Recordati’s commitment to sustainable business practices.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical company that operates in the Specialty & Primary Care and Rare Diseases sectors. The company is recognized for its focus on niche pharmaceutical products, particularly in the areas of urology, endocrinology, and onco-hematology, and is expanding its market reach globally.
YTD Price Performance: 16.70%
Average Trading Volume: 25,848
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €12.19B
See more data about REC stock on TipRanks’ Stock Analysis page.
